Unless all coronavirus has a certain cough signature which we don't know so this is likely what RAP are looking at, they do spend $900K out of the $1.6M per quarter on R&D you know. And it will also save a lot of life as it can more accurately detect those that have LTRI and pneumonia and give them the limited ICU beds instead of to a patient that don't have them.
Ann: ResApp Builds European Market Presence, page-68
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 196 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)